Chameleon BioSurfaces secures funding

Chameleon BioSurfaces, which develops biotechnology for medical device companies, has raised up to £475,000 from an investment syndicate led by London Seed Capital.

The funding enables Chameleon to continue its development and commercialisation programme.

The investment syndicate includes members of the London Business Angels network, the London Business Angel EIS Tracker Fund, Iceni Seedcorn Fund, Rainbow Seed Fund, GEIF Ventures and existing investors and shareholders in the company.

Based in Norwich, Chameleon specialises in polymer coatings and surface design for implantable medical devices. It was represented by law firm Taylor Vinters.

Jason Ball, investment director of London Seed Capital, comments: ‘We are very pleased to have led the syndicate in this significant round of investment for Chameleon BioSurfaces.

‘The company has a strong management team, headed by founder Dr David Hollinworth, and I know that these funds will be applied to enable the business to make a significant impact on the medical devices industry with its top-flight technology.’

Marc Barber

Marc Barber

Marc was editor of GrowthBusiness from 2006 to 2010. He specialised in writing about entrepreneurs, private equity and venture capital, mid-market M&A, small caps and high-growth businesses.

Related Topics